Natrilix brings down blood pressure not the patient...

Natrilix alone achieves successful control in 7 out of 10 patients.

Presentation
Pink biconvex sugar-coated tablets each containing 2.5 mg indapamide hemihydrate.

Uses
For the treatment of hypertension. Natrilix may be used as sole therapy or combined with other antihypertensive agents.

Dosage and Administration
Adults: The dosage is one tablet daily, containing 2.5 mg indapamide hemihydrate, to be taken in the morning. The action of Natrilix is progressive and the reduction in blood pressure may continue and not reach a maximum until several months after the start of therapy. A larger dose than 2.5 mg Natrilix is not recommended as there is no appreciable additional anti-hypertensive effect. The co-administration of Natrilix with diuretics which may cause hypokalaemia is not recommended.

Children: There is no experience of the use of this drug in children.

Contra-indications, Warnings, etc.
There are no absolute contra-indications to the use of Natrilix but caution should be exercised when prescribing Natrilix in cases of severe renal or hepatic impairment.

Side Effects
Reported side effects have been gastrointestinal and neurological and are mild in nature.

Basic NHS Code
30 tabs. £5.29...

Product Licence
0027/0002 FORM

Caring for the hypertensive patient – one tablet daily.
CLASSIFIED ADVERTISEMENTS AND NOTICES

Classified Advertisements are welcomed and should be sent to: Classified Advertising Manager, T.G. Scott and Son Limited, Media Managers, 30-32 Southampton Street, London WC2E 7HR. Telephone: 01-240 2032. Copy must be received six weeks before the 1st of the month of issue to ensure inclusion. Every effort will be made to include advertisements received after this date but publication cannot be guaranteed and the advertisement may have to be held over to the following issue.

The charge for space in this section is £6.35 per single column centimetre, plus 30p if a box number is required, plus VAT at 15%. Fellows, Members and Associates of the Royal College of General Practitioners may claim a 10% reduction. Replies to box numbers should be sent to the above address, with the box number on the envelope.

The inclusion of an advertisement in this Journal does not imply any recommendation and the Editor reserves the right to refuse any advertisement. All recruitment advertisements in this section are open to both men and women.

THE ROYAL COLLEGE OF GENERAL PRACTITIONERS
WEST OF SCOTLAND FACULTY
(in collaboration with the West of Scotland Committee for Postgraduate Medical Education)

PREPARATION COURSE FOR THE MRCGP EXAMINATION

Friday 6th to Sunday 8th February 1987
Normandy Hotel, Renfrew

The above course is intended for general practitioners who plan to take the Membership Examination of the Royal College of General Practitioners. The number of participants is limited and early application is advised. Preference will be given to applicants who have not had the opportunity to attend trainee half-day release sessions dealing with preparation for the MRCGP examination. The course is residential and Section 63 approval has been sought. The course will take the form of advice on preparation and a mock examination.

Further details and an application form may be obtained from:
Mrs E. Watt
Postgraduate Medical Education Office
The University of Glasgow
Glasgow G12 8QO
Telephone: 041-339 8855, Ext. 5275

COURSES IN HOMOEOPATHY

This new series of courses will offer training in Homoeopathic Therapeutics with an emphasis on practical aspects, especially relevant to general practice. The introductory course (in two parts) may be taken as a self contained unit sufficient for some simple prescribing, or can be regarded as the foundation for follow up courses later in the year.


For information, please contact — Education Convener, Faculty of Homoeopathy (Scottish Branch) Glasgow Homoeopathic Hospital, 1000 Great Western Road, Glasgow G12 0NR.

MRCGP PRACTICE EXAMS

New book now available edited by John Sanders. General Practice Tutor, Stockport, Cheshire and Secretary of Education Subcommittee, North West Faculty RCGP. This book contains essential advice and tips for every MRCGP candidate — two complete MRCGP practice examinations with marking system, answers and teaching explanations. two MEQ papers, two PTO papers both with samples and marking schedules. Oral and Log Diary techniques and presentations revision index and recommended book list. Send cheque now for £7.95 plus 75p p&p. The books are despatched the same day by first class mail.

Dept. GP PasTest Service. 304 Galley Hill, Hemel Hempstead, Herts HP1 3LE. Tel: Hemel Hempstead (0442) 52113.

ROYAL POSTGRADUATE MEDICAL SCHOOL
(University of London)

COURSE IN ADVANCED MEDICINE FOR GENERAL PRACTITIONERS

2-6 February 1987

Applications are invited from General Practitioners for the above course which will be held at the Royal Postgraduate Medical School, Hammersmith Hospital.

The course will aim to cover recent advances in many aspects of medicine. Lectures on a wide range of subjects will be given by senior staff and their content will reflect the current clinical and research interests of the School.

Course Organiser: Professor G.F. Joplin (Clinical Tutor).

Application forms and further details are available from:
School Office (SSC)
Royal Postgraduate Medical School
Hammersmith Hospital
Du Cane Road
London W12 OHS
Telephone: 01 740 3118

GP's will be charged a catering fee of £40. Non-GP's will be charged a course fee of £185.

THIS COURSE HAS FULL SECTION 63 APPROVAL
THE FIRST STEP
Introducing new ‘Monit’ LS
Low Strength ‘Monit’
for your new mononitrate patients
Rx. ‘Monit’ LS 1 tablet b.d. initially

Prescribing Notes for ‘Monit’ and ‘Monit’ LS

Dosage
PROPHYLAXIS OF ANGINA – Usually one ‘Monit’ tablet two or three times daily. For patients not receiving prophylactic nitrate therapy, the initial dose should be one ‘Monit’ LS tablet twice daily. Maintenance dose in individual patients will be between 20 and 120 mg daily.
ELDERLY PATIENTS – Dosage requirements may be reduced, especially in patients with hepatic or renal impairment.

Contra-indications
A known sensitivity to the drug or isosorbide dinitrate.

Warnings
The following adverse effects may be seen with nitrate therapy: 1. Cutaneous vasodilatation, headache, dizziness and weakness may occur. If headache is a problem, a temporary lowering of the ‘Monit’ dose may be necessary. The incidence of these effects is highest at commencement of treatment and tends to decline with time. 2. Postural hypotension may occur, especially with high doses. 3. Nitrates preparations can act as physiological antagonists to noradrenaline, acetylcholine, histamine and other agents. 4. Dry rash and/or exfoliative dermatitis have been described rarely with isosorbide dinitrate and similar reactions might be expected occasionally.

Pregnancy and lactation: Nitrates should not be given to pregnant women and nursing mothers unless essential.

Product Licence Numbers and Basic NHS Cost:
‘Monit’ tablets each containing 20 mg of isosorbide mononitrate 29/194 in calendar packs of 56 tablets, £4.79 or bottles of 100 tablets, £8.40.
‘Monit’ LS tablets each containing 10 mg of isosorbide mononitrate 29/194 in calendar packs of 14 tablets, £0.83.

‘Monit’ and ‘Monit’ LS are trade marks.

Further information is available on request from the Company.

Stuart Pharmaceuticals Limited
Stuart House, 30 Alderley Road, Wilmslow, Cheshire SK9 1RE.